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ABSTRACT
In 2017, it is estimated that breast cancer will be the most prevalent newly
diagnosed cancer in females, at 30% in the U.S. alone1. From the early 1990s to 2014
the death rate in females from breast cancer has dropped by 10% but still stands as the
second highest cancer related death in females in the U.S.2. One of the biggest hurdles
in breast cancer research is disease heterogeneity. New mechanisms of disease
development and progression are encountered frequently. One mechanism studied in
the past decades is epigenetics. It has been theorized that the cancer epigenome can
maintain an abnormal state and possibly cooperate with genetic mutations3 and/or
epigenetic modulators can be mutated which may become critical for cancer survival 4.
MLL1 (KMT2A), an epigenetic modulator that regulates gene expression by
trimethylation of H3K4 near gene promoters, has recently been implicated in cancer.
Data mining of publicly available primary patient databases revealed that high MLL1
expression is associated with decreased probability of recurrence-free survival in triple
negative breast cancer (TNBC). In breast cancer cell lines that represent different
breast cancer subtypes we tested the efficacy of pharmacological MLL1 inhibition and
MLL1 knockdown. Our data suggests that MLL1 is crucial for anchorage independent
growth of the MDA-MB-468 cell line and this is not dependent on high MLL1 expression.
The use of an MLL1-specific inhibitor in combination with standard of care
chemotherapeutic agents was shown to be more effective for all breast cancer cell lines
tested; the drugs could be used at much lower doses when combined. Some of the
many MLL1 specific gene targets (ABCG2, AMIGO2 and EMP1) were interrogated for
vi

changes in gene expression with MLL1 inhibition. To our surprise the observed changes
varied between the cell lines suggesting that MLL1 inhibition differentially affects
expression of specific genes in different cellular contexts. In conclusion, we
demonstrate that MLL1 may be a viable target for breast cancer therapy in combination
with standard of care agents. We also suggest that MLL1-dependent gene expression
mechanisms could decrease drug resistance or impact cell survival.
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CHAPTER ONE
LITERATURE REVIEW
Breast Cancer and Epigenetics
About 12% of women in their lifetime will develop invasive breast cancer5. In the U.S
alone it is estimated that in 2017 nearly 250,000 women will be diagnosed with breast
cancer and over 40,000 women will die because of the disease5. A major challenge for
breast cancer is that the tumors are highly diverse which possibly renders treatment
difficult. Classification systems have been discovered through DNA microarray gene
expression analysis of primary patient tumor samples that identifies hormone receptor
status and many other gene expression profiles6. This data gave rise to gene
expression profiles with specific clinical prognosis and more optimized treatment
modalities7. Initially 4 breast cancer subtypes were identified which include estrogen
receptor (ER) positive or luminal type, basal-like, normal-like and HER2 positive6. Each
subtype poses a different clinical probability with regard to overall and/or relapse-free
survival, with basal-like and HER2 positive having the worst and luminal type having the
best7. Even with major advancements in understanding breast cancer over 500,000
women died in 2011 worldwide, and the year after that, more than 1.7 million were
newly diagnosed with breast cancer8.
Recently epigenetics has been implicated in breast cancer. One potential benefit
of epigenetic therapy is based on the premise that epigenetic changes are reversible
and can potentially recover cells from an abnormal state9. These epigenetic
abnormalities involve DNA methylation, chromatin remodeling and histone modifications
which all can have effects on gene expression. One example is that abnormal histone
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modifications at H3K4 could be critical for breast cancer growth and were driven by
missense p53 mutations10.
Wild Type MLL1

The first discovery of MLL1 was in 1991 through analysis of chromosomal
translocations at chromosome breakpoint 11q2311. Two of the critical functional
domains of the MLL1 protein are the plant homeodomain (PHD) zinc fingers and the
Su(var)3-9, Enhancer-of-zeste and Trithorax (SET) domain. The PHD fingers are
involved in chromatin recognition including protein interaction with histones and the SET
domain has methyltransferase activity specific for lysine 4 on histone 3 (H3K4). MLL1 is
over 4000 amino acids in length and in cells it is cleaved by taspase 1 to generate a 300
kDa N-terminal and a 170 kDa C-terminal fragment12. The fragments hetereodimerize
and complex with critical functional components WD repeat domain 5 (WDR5),
retinoblastoma binding protein 5 (RBBP5), absent, small, or homeotic-like (ASH2L) and
multiple endocrine neoplasia 1 (MEN1)13. More specifically, at the C-terminal domain of
MLL1 it has been shown that RBBP5 and ASH2L dimerize and bind weakly to MLL1
and WDR5 acts as a bridging molecule that stabilizes the interaction and complex
formation14. MEN1 binds to the N-terminal domain of MLL1 and has shown to be critical
for transcriptional regulation of the complex in MLL-fusion15. Overall, MLL1 regulates
gene transcription through methylation specifically at H3K4. MLL1 binds the promoter
region of many genes and regulates their expression, including some of the HOX genes
which have been tightly associated with development 16.
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MLL1 and Cancer
The majority of studies of MLL1 function to date have been focused on MLL1 fusion
leukemias. MLL1 fusion proteins drive leukemogenesis by the dysregulation of certain
genes, but wild type MLL1 in leukemia has become of interest as it has distinct roles in
transcriptional programs that contribute to the leukemia gene expression program17.
Outside of leukemia, MLL1 has been implicated in many cancer pathways in many
different cancer types. MLL1 has been shown to contribute to the tumorigenic potential
of glioblastoma stem cells specifically through HOXA10 gene activation18. Also, it has
been observed that MLL1 expression levels are high in cervical carcinoma and a
consequence of high MLL1 expression in cervical carcinoma cell lines is transactivation
of CCND1, which promotes cell proliferation19. In addition, MLL1 genetic knockdown
greatly reduced tumor growth in vivo of a cervical cancer xenograft and decreased key
proangiogenic factors20. In an oncogene-induced senescence (OIS) model of lung
fibroblast cells and MCF7 breast cancer cells, MLL1 was shown to repress the
expression of some genes required for DNA replication and DNA damage response
(DDR) which greatly inhibits cells to undergo the senescence-associated secretory
phenotype (SASP)21. SASP has positive implications on proliferation of malignant
cells21. Another report associates MLL1 with metastasis of hepatocellular carcinoma
(HCC) through increased expression of MLL1 target genes MMP1 and MMP322. MLL1
has also been shown to regulate kinesin family proteins in breast cancer cell lines that
drive proliferation and tamoxifen resistance23.
All together MLL1 may have critical roles contributing to the cancer phenotype of
many different cancers. These roles seem to include the epigenetic gene regulatory
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function MLL1 at certain target genes that then drive critical cancer cell survival
mechanisms.
Some MLL1 Targets and Cancer

MLL1 is an epigenetic regulator that controls the expression of many genes. This
study set out to study three that were shown to be specific MLL1 targets through ChiPseq of MLL-AF9 leukemia cells17. These three genes listed below have been were
greatly changed in expression with MLL1 inhibition as shown by RNAseq in MLL-AF9
leukemia cells17.

ABCG2.

ABCG2, also known as the breast cancer resistance protein, is an ABC
transporter of which the ABC family are strictly substrate exporters24. ABCG2 has been
tightly

associated

with

multi-drug

resistance

(MDR)

and

more

specifically

chemoresistance through study of ABCG2 substrates24. The list of known substrates
includes anti-cancer agents such as: topoisomerase inhibitors, anthracyclines,
camptothecin (CPT) analogs, tyrosine kinase inhibitors (TKI), and antimetabolites24.
Since the initial discovery of ABCG2 in 199825, ABCG2 has been implicated in other
cancer types, an extensive list MLL1 targets ABCG2 in MLL-AF9 transduced leukemia
cells and has been shown to positively regulate its expression 17. This would suggest
that high MLL1 expression may increase the ABCG2 expression and that inhibiting
MLL1 may decrease ACBG2 expression.
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AMIGO2.

Adhesion molecule Ig-Like 2 (AMIGO2) is a transmembrane protein involved with
the PI3-AKT signaling pathway, angiogenesis and cell endothelial cell survival27.
AMIGO2 functions as a scaffold for 3-phosphoinositide dependent kinase 1 (PDK1)
membrane localization and subsequent activation of AKT27. Knockdown of AMIGO2 in
endothelial cells greatly reduced migration and capillary network formation27. In an
osteosarcoma cancer cell model upregulation of AMIGO2 increase attachment to liver
endothelial cells which increased metastasis to the liver28. In MLL-AF9 transduced
leukemia cells MLL1 was shown to be a direct target of AMIGO2 and specifically
activated transcription17.

EMP1.

Epithelial membrane protein 1 (EMP1) is an MLL1 target in MLL-AF9 transduced
leukemia cells17 and its expression increased 7-fold upon MLL1 inhibition suggesting
MLL1 may have a suppressive gene transcription role at this gene17. Gastric carcinoma
tissue from primary patients showed decreased EMP1 expression, and this decrease
was associated with tumor invasion, lymph node metastasis, clinical stage and
histological grade29. In breast cancer, EMP1 is decreased in patient samples and
correlates negatively to overall survival30. Increased expression of EMP1 in the MCF7
breast cancer cell line caused increased apoptosis and decreased invasion and
migration30.

6

Targeting Epigenetics in Cancer
Epigenetic-targeting drugs such as DNA methyltransferase (DNMT) inhibitors
and histone deacetylase (HDAC) inhibitors have been shown to be effective in breast
cancer cells31-32. Studies have shown that these epigenetic drugs in combination with
cytotoxic agents may be effective32. Arce et al (2006) demonstrated that treatment of
breast cancer patients with

DNMTi and HDACi along

with doxorubicin or

cyclophosphamide was well-tolerated and important proapototic genes like TP53 and
CDKN1A (p21) were upregulated while drug resistant genes like ABCB5 were
downregulated33. Another clinical trial with HDAC inhibitor vorinostat with paclitaxel, a
tubulin targeting molecule, and bevacizumab, an anti-VEGF-A antibody, results in 50%
of patients achieving a partial or complete response for those with recurrent metastatic
breast cancer34. An epigenetic drug that disrupts the interaction of MLL1 and menin, MI2, has been shown to abrogate MLL acute leukemia development in a murine model
system in vivo35. To our knowledge, use of MI-2 in breast cancer cells has only been
reported in the context of missense p53 mutation status 10. Targeting MLL1 specifically
in breast cancer could alter gene expression programs that are necessary for specific
aspects of the breast cancer cell survival. It also is possible that the epigenetic-targeting
drug MI-2 could be efficacious in combination with chemotherapeutic agents for breast
cancer therapy.
In this study, I mined gene expression databases to determine whether MLL1
expression was correlated with clinical subtypes, prognosis, or treatment status in
breast cancer. Also in this study, by investigating a panel of breast cancer cell lines for
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proliferation and anchorage independent growth with the use of MI-2 and MLL1
knockdown, I aimed to elucidate the potential of using MLL1 specific inhibitors for breast
cancer therapy. Furthermore, I determined whether breast cancer cells were more
sensitive to combinatorial treatment with MLL1 inhibition plus standard of care
chemotherapy agents. Several genes that are known direct MLL1 targets that may have
roles in drug resistance, proliferation and metastatic potential were interrogated for gene
expression changes in breast cancer cells upon MLL1 inhibition. Our results indicate
that MLL1 could be a viable target in specific types of breast cancer and combinatorial
treatment is more efficacious, requiring less drug for effective inhibition.
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CHAPTER TWO
METHODS
Cell Lines and Culture Conditions.
Six breast cancer cell lines (MDA-MB-468, MDA-MB-231, BT-549, T47D, MCF7,
ZR-75-1) were generously donated by Dr. Clodia Osipo (Loyola University Chicago) and
thawed from low passage cultures stored in liquid nitrogen. All the cell lines were
cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin (4.0 mM L-Glutamine, 4500 mg/L Glucose). Cells
were cultured in 10 cm2 plates with passage every 3-5 days. Trypsin (0.05%) was used
to detach cells.
RNA and cDNA Preparation.
RNA was isolated using 500µL to 1mL of Trizol (SIGMA; catalog # T9424),
depending on cell number isolated, using manufacturer’s protocol. cDNA synthesis was
competed using Applied Biosystems High Capacity cDNA Reverse Transcription Kit
(catalog #: 4368814)
qRT-PCR Analysis.
Applied Biosystems Taqman Fast Advanced Master Mix protocol was followed.
The Quant Studio 6 Flex machine and software were used and analysis was done using
the Comparative CT Method37. For all analysis, the 2-ΔΔCt method was utilized to
compare cell lines and gene expression following protocol37.
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Taqman primer probes sourced from Integrated DNA Technologies were used for
the following genes listed below in Table 1. Taqman Master Mix (Applied Biosystems)
(Ref #:4444557) was used in each reaction following manufactures protocol.
RefSeq Accession

Exon

Gene

Assay ID
#

Location

ABCG2

NM_001257386 (2)

6-7

Hs.PT.58.1283359

AMIGO2

NM_001143668 (1)

1-2

Hs.PT.58.333002

β2M

NM_004048

2-4

Hs.PT.58v.18759587

EMP1

NM_001423 (1)

1-2

Hs.PT.58.3020024

ISL1

NM_002202 (1)

5-6

Hs.PT.58.2143768

KMT2A(MLL1)

NM_005933 (2)

11-13

Hs.PT.58.22285060

MEN1

NM_130799 (7)

3a-4

Hs.PT.58.22752253

Table 1. List of taqman primer probe sets
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shRNA Mediated Knockdown.
pGFP-C-shLenti plasmids containing MLL1 specific 29mer knockdown short
hairpin sequences were obtained from ORiGene (Catalog #: TL311462). 293T cells
were transfected using Clontech calcium phosphate transfection reagents following
manufacturer’s protocol (Catalog #: 631312). Plasmids and reagents were incubated for
3 days before harvesting virus containing media on the 4th and 5th day post transfection.
Two constructs within similar knockdown efficiency (determined in 293T cells) were
used and are listed in Table 2 below.
29mer ID

shRNA target MLL1 sequence

TL311462A

CCACTCCATTCTGGAACAAGGTTTGATAT

TL311462D

TGTCTCATCACCAGCACTTACATTCCTTC

Table 2. shRNA expression vector pGFP-C-shLenti plasmids

FACS.
Fluorescence Activated Cell Sorting was performed on by BD Aria IIIu using
FACSDiva (version 6.1.3) according to manufacturer’s protocols. Knockdown constructs
co-expressed GFP, therefore GFP+ cells were sorted and used for functional assays
following shRNA mediated knockdown.
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Cell Viability Assay.
Promega Cell Titer-Glo 2.0 reagent was used to assess ATP content as an
indicator of metabolically active cells. Greiner Bio One 96-well clear bottom white walled
plates (Lot#: E16023C5) were used for cell culture. Cell Titer-Glo 2.0 reagent was
dispensed into the 96-well plate following manufacturer’s protocol. The plates were read
on BMG Labtech POLARstar Omega readers using BMG Labtech Omega software
version 1.02. Luminescence was determined and quantification and analysis was
completed using Microsoft Excel.
Colony Formation Assay.
Stem Cell Technologies Methocult H4100 was used for colony suspension in 12well non-tissue culture treated plates (Cyto-One). Cells were subjected to single-cell
suspension by using 0.125% trypsin and vigorous pipetting. Once in single cell
suspension cells were plated in triplicate (2,500-5000 cells/well) and allowed to incubate
for 8-14 days. High quality images (1792x1374) using AmScope MU100 camera and
AmScope software were captured and colonies were counted using 7 images per well
(21 images per triplicate) and was used to represent the entire plate.
Drugs.
Carboplatin from Sigma Aldrich (C2538: Lot # SLBL7058U), 4-hydroxy-tamoxifen
(4OHT) (Sigma Aldrich, Catalog #: H7904) and MI-2 from Selleckchem (Cat No. S7618)
were used alone and in combination to determine IC50 for each cell line. Greiner Bio
One 96-well clear bottom white walled plates were used and IC 50 calculations were
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completed using GraphPad Prism 7. Cells were treated with a range of 6-7 different
concentrations of each drug to determine an IC50. Once an IC50 was established the
combinatorial experiments treated cells with standard-of-care drugs and MI-2 alone and
together at each cell lines respective IC 50 and an additional set of wells used drugs in
combination at ½ the IC50.
Primary Patient Databases.
KMT2A (aka MLL1) (AffyID: 226981_at and 220546_at) was interrogated using
the Kaplan Meier Plotter software (www.kmplot.com) which includes microarray data
from 1809 cancer patients37. For each specific analysis breast cancer patient
microarrays were separated into either triple negative breast cancer (ER -/PR-/HER2-) as
selected individually in the restriction analysis menu box, luminal A (ER+/HER2-/Ki67low)
and luminal B (ER+/HER2-/Ki67high) as selected with the intrinsic subtype selector.
Analysis of recurrence-free survival probability of triple negative and luminal A or B
breast cancer was utilized as well as isolating treated and untreated patient samples.
Untreated patients are categorized by excluding chemotherapy, adjuvant and
neoadjuvant therapy. Treated patients included endocrine therapy and chemotherapy.
The high and low expression data was split at the median expression level.

CHAPTER THREE
REULTS
Aim 1: Determine whether MLL1 expression levels correlate with clinical
outcomes in breast cancer
Gene expression analysis and clinical outcomes from primary patient samples
are readily available through multiple different online repositories. I searched for MLL1
(KMT2A) expression level and clinical outcomes in breast cancer using the Kaplan
Meier plotter software37 that integrates information regarding microarray data and
clinical outcomes from GEO (Affymetrix microarrays only), EGA and TCGA. Figure 1
demonstrates the relationship between MLL1 expression (divided from the median) in
Luminal A/B and triple negative breast cancer (TNBC) plotting the probability for
recurrence-free survival. Both Luminal A and B (figures 1A and B) show a positive
correlation; higher MLL1 expression is associated with increased probability of
recurrence-free survival. In contrast TNBC (figure 1C) shows the opposite: higher MLL1
expression is associated with a decreased probability of recurrence-free survival.
Interestingly, if you divide the samples in this study between treated and untreated
patients, the negative correlation only lies within the samples isolated from post-treated
patients. Figure 1D represents TNBC patients that are classified as untreated and there
is no correlation with the probability of recurrence-free survival. If you limit the analysis
to only Luminal A and B primary patient samples (data not shown) there still is a positive
correlation between recurrence-free survival and higher MLL1 expression. These results
suggest that MLL1 may have different roles in different breast cancer subtypes with
regard to breast cancer recurrence and that higher MLL1 expression in treated TNBC
patients results in decreased probability of recurrence-free survival.
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Luminal A (treated)

B

— high (152)
— low (153)

— high (88)
— low (88)

Time (months)

TNBC (treated)

Time (months)

D

TNBC (untreated)

recurrence-free
survival probability

recurrence-free
survival probability

C

Luminal B (treated)

recurrence-free
survival probability

recurrence-free
survival probability

A

— high (27)
— low (27)

Time (months)

— high (28)
— low (28)

Time (months)

Figure 1. MLL1 expression in primary breast cancer patient samples with
correlation to recurrence free survival. MLL1 (Affy ID: 226981_at and 220546_at)
was assessed in Luminal A, B and TNBC patient samples and correlated with
recurrence-free survival. The x-axis represents time (months) and red and black bars
represent high and low expression, respectively, of MLL1. (A, B, C) excludes untreated
patients and (D) is only untreated patients with TNBC. TNBC is defined as ER -/PR/HER2-. Luminal A and B is defined by the 2013 St Gallen criteria (Luminal A:
ESR1+/HER2-/MIKi67 low; Luminal B: ESR1+/HER2-/MIKi67 high). Data was obtained
from Breast Cancer Res Treatment, 2010 123:725-31.
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Aim 2: Determine the effect of MLL1 knockdown and pharmacological inhibition
on breast cancer cell lines.
Recently MLL1 has been implicated in breast cancer and to a broader extent in
some other cancers. MLL1 was shown to drive breast cancer growth in in vivo breast
cancer cell line xenograft models and in vitro breast cancer cell lines10. MLL1 specific
inhibitors showed some promise in breast cancer cell lines in a missense mutant p53
dependent manner10. Also, MLL1 has been associated with cervical carcinoma and may
have roles in promoting tumorigenesis and metastasis directly through its interaction
with -catenin19. In addition, studies identified specific genes regulated by MLL1 that
were associated with the cancer phenotype. Dirks et al. (2012) suggest that MLL1 can
specifically regulate expression of HOXA10 and this process contributes to
tumorigenicity of glioblastoma stem cells. In the MLL1 fusion leukemia model MLL-AF4,
the

fusion

protein

upregulates

expression

of

MDR1

and

contributes

to

chemoresistance38.
With this information in mind I hypothesized that MLL1 is critical for in vitro
proliferation and growth of breast cancer cell lines. To test my hypothesis, I determined
the effect of MLL1 knockdown and MLL1 pharmacological inhibition on 6 breast cancer
cell lines that represent either the TNBC or luminal breast cancer subtypes. I have
measured the effects of manipulating MLL1 expression or function on the breast cancer
cell line proliferation, anchorage independent growth, migration, and response to
standard-of-care drugs. Table 3 describes the breast cancer cell lines used in this study.
Subtype and p53 status are included because the clinical information suggests a
subtype bias to MLL1 dependence and a recent report suggested that some missense

16
p53 mutations drive breast cancer cell line growth in vitro and in vivo through increasing
MLL1 expression10.

Breast Cancer
Cell Line

Breast Cancer
Subtype*

TP53 Status**

Additional mutations
and abnormalities ***

MDA-MB-468

Basal-like

missense
R273H

PTEN, RB1, SMAD4

MDA-MB-231

Basal-like

missense
R280K

BRAF (G464V),
CDKN2A (M521I), RAS
(G13D), p16, p14ARF

BT-549

Basal-like

missense
R249S

PTEN

T47D

Luminal A/B

missense
L194F

PIK3CA (H1047R),
p16meth

MCF7

Luminal A/B

WT

CDKN2A, PIK3CA
(E545K), p16, p14ARF,
AKT1amp, HDM2amp

ZR-75-1

Luminal A/B

WT

HDM2amp, CyclinD1amp

Table 3. Breast cancer cell lines used in this study
* Breast Cancer Res Treat (2013) 142:237-255, ** www.atcc.org, *** Breast Cancer Res Treat
(2010) 121:53-64 & www.atcc.org
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Basal MLL1 expression.
I determined the relative MLL1 expression between the cell lines used in this
study to see whether MLL1 was differentially expressed in unmanipulated cell lines that
represent luminal or basal breast cancer subtypes. Figure 2 represents the relative
basal expression of MLL1. As shown in Figure 2 the expression differs between the cell
lines and shows that luminal breast cancer cell lines have ~ 3-10-fold more expression
of MLL1 than the basal breast cancer cell lines assayed. The relative MLL1 expression
levels did not correlate with TP53 mutation status.

Figure 2. Basal MLL1 expression in breast cancer cell lines. Five independent
samples of each cell line were harvested at 70% confluency within a span of 2
months culture time. RNA was isolated using Trizol, cDNA synthesized and duplex
qRT-PCR performed normalized to β2M. For analysis, the 5 independent replicates
were combined. The 2-ΔΔCt was utilized and the lowest MLL1 expressing cell line
(MDA-MB-468) was set to one.
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shRNA-mediated MLL1 knockdown.
MLL1 knockdown was mediated by specific shRNA lentivirus. Isolation of
transduced cells was achieved through FACS sorting of GFP + cells 48 hours post
transduction. Figure 3A represents the forward and side scatter gates indicating live
cells (left) and the gates set for GFP+ (virally transduced) cells (right). MLL1 knockdown
was confirmed through qRT-PCR analysis (Figure 3B). shRNA construct # 2 achieved
~50% knockdown reproducibly within all the cell lines and shRNA construct #1 achieved
on average 40% knockdown.
Figure 3C represents the anchorage independent growth (BT-549 is not included
as it did not form colonies in our system, see methods) of all breast cancer cell lines
used in this study. MDA-MB-468 cell line was the only cell line affected by MLL1
knockdown with almost no detectable colonies. As shown in figure 4A with both shRNA
constructs there are no detectable colonies after incubation in methylcellulose for 14
days. The T47D cell line seems to have a dramatic effect only with construct # 2 that is
reproducible. This could be explained this cell line needing a critical amount of MLL1 or
it could be off target effects of the shRNA construct. Nonetheless our data suggests
conclusively that MLL1 is necessary for anchorage independent growth of the MDA-MB468 cell line.
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Figure 3. Effect of MLL1 KD on anchorage independent growth and cell proliferation. (A) FACS forward and side
scatter (left) and GFP+ cells that were sorted and collected (right). (B) MLL1 knockdown confirmed by qRT-PCR.
Analysis was carried out by the 2-ΔΔCt method setting scramble shRNA-infected cells MLL1 expression to one. RNA was
isolated 3 days post infection which include two days of viral incubation and one day post sorting. Numbers above MB468 and MB-231 sh#1 represent the p value. (C) Anchorage independent growth as assayed by colony number per
field. Each field contained seven images with each experiment completed in triplicate. Number within the scramble bar
represents the number of independent replicates combined in the data. (D) ATP content as assayed with Cell-Titer Glo
2.0 reagent. Numbers within bars represent the independent replicates combined in the data. (p < 0.05 *, p < 0.01 **)

A
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B
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Figure 4. Images of breast cancer cell lines grown in methylcellulose and in liquid culture following shRNAmediate MLL1 knockdown. (A) GFP+ colonies (top) after 8-14 days in methylcellulose medium with corresponding
bright field images (bottom) for each transduced construct. (B) GFP+ breast cancer cells grown in tissue culture treated
plates 4 days after sorting (6 days post infection) (top) and corresponding bright field images (bottom) for each
transduced construct.
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Another property of breast cancer cell lines is their ability to rapidly proliferate
endlessly. Proliferation requires metabolically active cells which produce ATP. I
measured the ATP content of breast cancer cell lines following MLL1 knockdown. In
figure 3D, I demonstrate that shRNA-mediated MLL1 knockdown did not have any effect
on the ATP content of breast cancer cells in culture 4 days post isolation of transduced
cells (6 days post infection). Figure 4 shows cells in culture 4 days post sorting and 6
days post infection indicating GFP+ directly before isolation and analysis. In conclusion,
MLL1 expression level may not affect the metabolic activity of these breast cancer cell
lines, which suggests it has no effect on proliferation.
Pharmacological MLL1 inhibition.
I hypothesized that inhibition of MLL activity would inhibit the proliferation of the
breast cancer cell lines used in this study as measured by ATP content after incubation
with MI-2, a menin-MLL1 inhibitor that disrupts the activity of MLL1. Prior to use of the
menin inhibitor MI-2, I had to determine sensitivity of each of the cell line in this study to
the inhibitor. To determine the cell line sensitivity, I determined an IC50 for each cell line
as determined by measuring ATP content after 3 days of exposure to MI-2. An IC50 is
calculated by using a range of at least six concentrations of any given inhibitor and
generate a dose-response curve that can be interrogated for a concentration of drug at
which cell viability can be inhibited by 50%. Figure 5A represents IC50 data of each cell
line. The MDA-MB-468 cell line was the most sensitive, with an IC50 of 11.3  4.5 M,
and the ZR-75-1 cell line was least sensitive with an IC50 of 40.6  4.7M. Figure 5B
demonstrates an example of the IC50 sigmoidal curves generated for each cell line.
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The basal expression level of MEN1 was relevant to determine because the MI-2
inhibitor binds to menin and disrupts its interaction with MLL1. Figure 5C demonstrates
the basal MEN1 expression of the cell lines used in this study. I found that all cell lines
expressed MEN1. However, there were differential levels of MEN1 expression between
the breast cancer subtypes. The luminal subtype cell lines expressed a higher level of
MEN1 and the triple negative subtype cell lines expressed less MEN1. The expression
of MEN1 did not correlate with MI-2 sensitivity and breast cancer cell lines tested have a
varying amount of sensitivity to MI-2. These data suggest that MLL1 inhibition has an
effect on proliferation of one breast cancer cell line and does not correlate with breast
cancer subtype or overall expression of MLL1 (Figure 1) or MEN1 as determined by the
IC50 and anchorage independent data.
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Figure 5. IC50 for each breast cancer cell line using MI-2. (A) IC50s for each cell
line. Each point represents an independent replicate IC 50 and the middle bar is the
mean. (B) Shows examples of IC50 calculations with the generated sigmoidal curve fit
line. (C) (pink = TNBC; blue = luminal) Represents the MEN1 (menin) expression of
each cell line. The lowest MEN1 expressing cell line was set to 1 and therefore fold
expression is displayed (n = 3). (p < 0.05 *, p < 0.01 **, p < 0.001 ***)
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Next, I investigated if MI-2 could have an effect on anchorage independent
growth of the cell lines used in this study. Figure 6A represents the anchorage
independent growth and colonies formed. Figure 6B is the calculation of colonies
formed represented as a percent of vehicle control. Similar to what was seen with the
cell viability IC50 calculations, the MDA-MB-468 cell lines is the most sensitive. In
contrast, the other cell lines are relatively insensitive to MI-2 treatment, with an inhibitory
effect only observed at the highest concentration tested, 50uM. One cell line, ZR-75-1,
actually had an increase in the colony forming activity following MI-2 treatment at
intermediate concentrations (12.5uM and 25uM) (Figure 6B).
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Figure 6. Anchorage independent growth of breast cancer cell lines following MI-2
treatment. (A) (pink = TNBC; blue = luminal) Relative colony forming ability, calculated
from combining at least 3 independent experiments. (B) Images of colonies formed 8-14
days post plating in methylcellulose with 4X objective. (p < 0.05 *, p < 0.01 **)
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Overall MLL1 and its interaction with menin is critical for the MDA-MB-468 cell line’s
anchorage independent growth but not the other breast cancer cell lines tested.
Gene expression changes in cells treated with MI-2.
I hypothesized that treatment of breast cancer cell lines with the menin inhibitor
MI-2 would alter expression of MLL1 target genes, particularly those targets that could
impact proliferation, drug resistance and anchorage independent growth of breast
cancer cell lines following treatment with the MLL1/menin inhibitor. Recently, in an MLLAF9 transduced leukemia cells MLL1 direct targets were assayed by ChIP-seq, and
RNA-seq analysis was done on cells treated with MI-217. MLL1 has many different
target genes, and has been shown to both positively and negatively affect expression of
its targets. To our knowledge, this is the first exploration of changes in gene expression
following MI-2 treatment of some MLL1 target genes in the breast cancer cell lines used
in this study. AMIGO2, ABCG2, EMP1 and ISL1 were assayed by RNA isolation
followed by qRT-PCR analysis after treating cells with MI-2 at their respective IC50
concentrations for four days. First, it was necessary to examine the relative gene
expression of each gene selected within the cell lines. I hypothesized that cells with
higher MLL1 expression (luminal type) should have higher ABCG2, higher AMIGO2,
and lower EMP1. This hypothesis was driven by gene expression changes observed in
MLL-AF9 transduced cells treated with MI-217. Figure 7A-C represents the relative basal
expression of each gene assayed. Figure 7A represents ABCG2, an ABC transporter,
also known as the breast cancer resistance protein, known to function as an efflux
component, pumping target molecules from the cytoplasm to the extracellular space.
Fold expression changes should keep in mind the relative expression of each gene
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within cell lines. As expected cell lines with higher MLL1 expression showed higher
ABCG2 expression (Figure 2; Figure 7A). For example, Figure 7A shows that MCF7
and ZR-75-1 have nearly 200-fold more expression of ABCG2 than the other cell lines.
The observed 0.8 and 0.5-fold reduction (MCF7 and ZR-75-1, respectively) is much
greater in absolute number than the 0.5-fold reduction in BT-549 cell line (Figure 7D).
Low EMP1 (epithelial membrane protein 1) expression has recently been reported to
correlate with poorer 5-year overall survival in colorectal cancer patients29 and has been
shown to increase more than 7-fold upon treatment of MLL-AF9 transduced leukemia
cells treated with MI-217. In only one cell line, T47D, do we see this similar trend to the
MLL-AF9 transduced cells (Figure 7E). It was also expected that cells with higher MLL1
expression should have lower EMP1 because MLL1 was recently shown to negatively
regulate EMP1 expression17 (Figure 7B). Figure 7C shows basal AMIGO2 expression
within the breast cancer cell lines used in this study. A 3.66-fold decrease in expression
in MLL-AF9 transduced cells has been reported17. I anticipated a decrease in
expression upon MI-2 treatment but observed the opposite (Figure 7F). In
osteosarcoma cell lines, decreased AMIGO2 has been reported to decrease migration
and tumorigenicity and upregulation has been shown to facilitate attachment to liver
endothelial cells28.
Specifically, for ABCG2 the cell lines BT-549, MCF7 and ZR-75-1 demonstrated
a decrease in expression upon MI-2 treatment. The relative of expression of MLL1
correlates with the basal level expression of ABCG2 as the cell lines with the highest
expression of MLL1 had the highest expression of ABCG2. Inhibition of the menin/MLL1
interaction was variable within the cell lines with regards to changes in ABCG2

29
expression. In conclusion MLL1 may activate gene expression of ABCG2 but inhibition
in the breast cancer cell lines used in this study does not always yield a decreased
expression of ABCG2.
Basal EMP1 expression of correlated with basal MLL1 expression in the breast
cancer cell lines used in this study with regards to its suggested function in MLL-AF9
leukemia cells17 as a repressor. High MLL1 expressing cells had the lowest expression
of EMP1. Changes in expression of EMP1 upon menin/MLL1 inhibition varied greatly
and was only seen in the T47D cell line. This suggest that the menin/MLL1 interaction
may not be critical for EMP1 gene repression in the other breast cancer cell lines in this
study.
Lastly, AMIGO2 expression did not correlate with relative MLL1 gene expression.
High expression of MLL1 did not demonstrate high expression of AMIGO2. Also,
inhibition of the menin/MLL1 interaction increased expression of AMIGO2 in multiple cell
lines suggesting its role as a gene repressor of AMIGO2.
The varied expression data of these cell lines upon menin/MLL1 inhibition
demonstrate that MLL1 function may vary in these breast cancer cell lines and that this
function may be different than what has been observed in MLL-AF9 transduced
leukemia cells.
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Figure 7. Changes in gene expression of validated MLL1 target genes ABCG2,
EMP1 and AMIGO2 in breast cancer cell lines treated with MI-2. Breast cancer cell
lines were treated at IC50 concentrations for 4 days. (A, B, C) Fold changes in genes
expression as compared to vehicle control (VC) and normalized to β2M. (D, E, F)
Basal level expression of each target gene in all the cell lines relative to BT-549 cell
line.
(n = 2; triplicate experiments) (p < 0.05 *, p < 0.01 **, p > 0.001 ***)
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Aim 3: Determine the combined effect of an MLL1 inhibitor with standard of care
chemotherapeutic agents on breast cancer cell lines.

I hypothesized that combined treatment of breast cancer cell lines with standard
of care chemotherapeutic agents plus MI-2 would be more efficacious than treatment
with the chemotherapeutic agents or MI-2 alone. I first generated IC50 data measuring
ATP content for cells treated with carboplatin, a molecule that cross-links guanine
bases, in the TNCB cell lines (MDA-MB-468, MDA-MB-231 and BT-549) and 4hydroxytamoxifen, an estrogen antagonist, for the luminal breast cancer cell lines
(T47D, MCF7 and ZR-75-1). I co-treated cells with the IC50 of each drug and then half
the IC50 and assayed for cell viability 4 days post treatment (Figure 8A). In all cell lines,
combinatorial treatment was more effective than either alone and most interestingly,
using combinatorial treatment at half the IC 50 was just as effective and in some cases
more effective than either treatment alone at the IC 50 (Figure 8A). This suggests that
combinatorial treatment can be effective at lower doses of both drugs. Figure 7B shows
the percent viability as compared to vehicle control of either drug at ½ of its IC 50 and
demonstrates that in most cell lines that half the IC 50 is not as effective as using
combinatorial treatment at half the IC50.
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Figure 8. Combinatorial treatment of breast cancer cell lines. Breast cancer cell
lines were treated at their IC50 concentration of either MI-2 or standard of care
chemotherapy agents Carboplatin and 4-OHT. Luminal breast cancer cell lines (right
3) were treated with 4-OHT and triple negative breast cancer cell lines (left 3) were
treated with Carboplatin. (A) Cell viability was measured using Cell Titer-Glo 2.0.
Significance stars above each bar represent a comparison to vehicle control. (B)
Results of cell viability relative to vehicle control of each individual drug using ½ the
IC50 concentration using the sigmoidal curve function generated when calculating the
IC50. (p < 0.05 *, p < 0.01 **, p > 0.001 ***, p < 0.0001 ****)
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CHAPTER FOUR
DISCUSSION
The focus of my research was to determine the possible role of MLL1 in breast
cancer. I first interrogated publicly available databases of breast cancer patient
microarray data that correlates clinical outcomes with MLL1 gene expression levels. My
datamining results indicate that there is a correlation between high MLL1 expression
levels and decreased probability of recurrence-free survival in triple negative breast
cancer patients that have been clinically treated. Therefore, I used a panel of breast
cancer cell lines to directly test my hypothesis that MLL1 expression and MLL1 function
are critical for multiple properties that likely contribute to breast cancer recurrence in
triple negative breast cancer patients.
First, I determined the basal MLL1 expression levels within these cell lines.
Initially, the hypothesis was that breast cancer cell lines with missense p53 mutations
would have the highest MLL1 expression as it has recently been shown that some
missense p53 mutations drive breast cancer growth through missense p53 proteins
acting at the promoter of MLL1 as a gene activator10. To our surprise the expression
levels of MLL1 were the opposite, those harboring missense p53 mutations (MDA-MB468, MDA-MB-231, BT-549, T47D) had much lower expression than cell lines with WT
p53 (MCF7, ZR-75-1) (Figure 1).
Two cancerous characteristics of these cancer cell lines is unlimited proliferation
and anchorage independent growth, both of which were assayed by genetic knockdown
or pharmacological inhibition. From these experiments, I concluded that anchorage
independent growth and proliferation does not depend on basal MLL1 expression
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levels. I found that the cell line with the lowest MLL1 expression, MDA-MB-468, was
most affected by manipulating MLL1 mRNA levels by knockdown or functionally with MI2. No other cell line was affected. Interestingly MLL1 KD in the MDA-MB-468 cell line
had no effect on proliferation but MI-2 did have an effect. This could be explained by the
KD efficiency of 50% and MI-2 concentration of 10M having a different effect on overall
MLL1 activity. Even with the lowest levels of MLL1 it could be that the MDA-MB-468 cell
lines requires a minimal critical amount of MLL1 for proliferation and anchorage
independent growth. Also, decreased activity of MLL1 could allow for de-repression or
activation of critical proliferation and/or anchorage independent growth genes. Overall
the anchorage independent growth of MDA-MB-468 cell line depends on MLL1 and this
can be recapitulated with pharmacological inhibition using MI-2.
In addition, breast cancer cell lines with missense p53 mutations (MDA-MB-468,
BT-549, HCC70) were shown to be sensitive to MLL1 KD with regards to cell
proliferation and anchorage independent growth while WT p53 harboring breast cancer
cell lines (MCF7, MDA-MB-175VII) were insensitive to these assays10. These data
suggest that cells lines with missense p53 mutations are sensitive to MLL1 KD. My data
shows the cell line MDA-MB-231 which harbors a missense p53 mutation is completely
insensitive to MLL1 KD and inhibition and yet has the same basal MLL1 expression
level as the MDA-MB-468 cell line. Also, the cell line T47D, has a missense p53
mutation and shows no sensitivity to MLL1 KD or inhibition with regards to anchorage
independent growth which has 3-fold more MLL1 expression than the MDA-MB-468 cell
line. Also, it was shown that primary patient samples with missense p53 mutations
displayed higher expression levels of MLL110. The trend presented from clinical data10
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does not match what is seen in these breast cell lines. Taken together these cell line
models could differ from the clinical samples in that different missense p53 mutations
act differentially at the promoter of MLL1 or may not associate at all. The function of
missense p53 mutations has been shown through KD of missense TP53 (which also
included WT TP53) decreases MLL1 expression10. Yet the data shown in my study
suggests that cell lines with missense p53 mutations have lower expression of MLL1 as
compared to cell lines with WT p53. It is possible that missense p53 mutations bind to
the promoter of MLL1 and play a repressive role and the data suggesting that missense
p53 mutations act as gene activators could be explained by missense p53 mutations
binding tightly (higher affinity) to the MLL1 promoter and by genetic manipulation of
missense p53 levels it exposes the MLL1 promoter to a more repressive protein.
Further studies need to confirm the role missense p53 mutations have in specific
cellular context.
Of the many MLL1 target genes a few candidates were measured that could
have an effect with regard to proliferation, metastasis and drug resistance. Emp1 and
Amigo2 have been implicated in cancer and are direct MLL1 targets in MLL-AF9
leukemia cells17. Low expression of EMP1 in breast cancer patient samples correlated
with poorer clinical prognosis and increased EMP1 in MCF7 cells decreased survival
and increased apoptosis30. MLL1 inhibition with MI-2 has been shown to increase
EMP1 expression over 7-fold in MLL-AF9 transduced cells and it is the top upregulated gene17. If EMP1 is a direct target of MLL1 then inhibition could de-repress
EMP1 driving expression and potentially decrease the survival of breast cancer cell
lines. We hypothesized that MI-2 treatment in breast cancer cells could dramatically
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increase the expression of EMP1. The only cell line which showed an increase in
EMP1 expression following MI-2 treatment was T47D. Interestingly the cell lines that
express the highest amount of MLL1 had the least amount of EMP1 expression
(MCF7 and ZR-75-1), supporting the suppressive role MLL1 may have on EMP1.
Further studies should focus on the role of EMP1 in breast cancer and understand if
increased expression results in decreasing cell survival and increase apoptosis.
Another gene interrogated for its role in adhesion was AMIGO2. Specifically, in
cancer its upregulation was shown to facilitate attachment to liver endothelial cells
and increase metastasis28. Amigo2 was shown to be a direct target of Mll1 and
downregulation on Amigo2 was observed upon Mll1 inhibition with MI-217. We
hypothesized that AMIGO2 would be downregulated in the breast cancer cell lines
with MLL1 inhibition but the opposite was observed. This suggest that MLL1 may
have a different role at AMIGO2 in these breast cancer cell lines. Further studies
should elucidate if AMIGO2 plays a role in liver metastasis in a breast cancer model;
liver is the second most common site of metastasis, around 20% 39. If so, this data
should caution MLL1 inhibition in treatment of cells that increase AMIGO2
expression upon MLL1 inhibition.
Looking back to the primary patient data mining results, tumor recurrence could
occur as a result of many different factors, one of which could be increased drug
resistance. One protein transporter, ABCG2, also known as the breast cancer
resistance protein, is an MLL1 target that we hypothesized would decrease upon MLL1
inhibition. ABCG2 functions as an efflux pump that pumps a wide range of molecules
from the cytoplasm to the extracellular space. In two cell lines, MCF7 and ZR-75-1, in
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which MLL1 expression is the highest, ABCG2 was downregulated upon treatment with
MI-2. We hypothesized that if MLL1 plays a role in drug resistance, not only by way of
decreased ABCG2, combinatorial treatment with carboplatin, a DNA damaging agent,
and 4-OHT, an estrogen antagonist, could be more effective and less drug would be
required in order to achieve a response. In all but the BT-549 cell line, combinatorial
treatment was highly effective and when using ½ the concentration of both drugs it was
just as effective as a high concentration alone, indicating a synergistic effect of
combinatorial treatment. We cannot conclude that the observed combinatorial results
are due to drug resistance as it is not known whether 4OHT or MI-2 are substrates of
ABCG2. Nonetheless combinatorial therapy can be efficacious for all cell lines
regardless of breast cancer subtype, MLL1 expression and missense p53 mutation
status. Further studies should look into other MLL1 target genes related to drug
resistance and then look to see if those genes play a role in breast cancer cell lines in
sensitizing cells to chemotherapy.
In conclusion, we suggest that MLL1 is a viable target in breast cancer and
more specifically MLL1 inhibition could enhance the response to standard of care
chemotherapeutic agents. Careful analysis of specific traits like anchorage
independent growth and proliferation through ATP content revealed that breast
cancer cell lines may vary in their utilization of MLL1. Breast cancer cell lines va ry by
mutation and therefore cell survival, progression, metastatic potential and drug
responsiveness could be very different when compared. This would also suggest that
not all cell lines depend on MLL1 for any of the above processes or, possibly a
worse scenario, MLL1 could be critical for one and increase another. We found that
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MLL1 is critical for anchorage independent growth of the MDA-MB-468 cell line. We
also observed decreased expression of ABCG2, also known as the breast cancer
resistance protein, in MCF7 and ZR-75-1 cell lines upon MLL inhibition suggesting
MLL1 in drug resistance and helping to support the observed combinatorial
treatment benefits. Gene expression changes in EMP1 could also play a negative
role in cell survival and AMIGO2 gene expression changes may forward a caution for
some cell lines. Overall cell lines may have different roles for MLL1 and each should
be carefully considered. The known MLL1 targets need to be assayed to understand
a more complete paradigm of MLL1 as treatment target in breast cancer.
.
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